Target mechanisms for new medications include increasing insulin sensitivity, reducing appetite, decreasing pro-inflammatory cytokines release by adipose tissue, and counteracting both endothelial dysfunction and thrombogenic effects of MS (68). The gene discussed is INS; the disease is endothelial dysfunction.